Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Organogenesis (ORGO : NSDQ)

• Company Description    Organogenesis is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. Number of Employees: 869

• Price / Volume Information    Yesterday's Closing Price: $5.18 Daily Weekly Monthly 20 Day Moving Average: 1,391,140 shares Shares Outstanding: 126.91 (millions) Market Capitalization: $657.41 (millions) Beta: 1.38 52 Week High: $7.08 52 Week Low: $2.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.28% 5.46% 12 Week 28.22% 26.15% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 85 Dan Road - Canton,MA 02021 USA ph: 781-575-0775 fax: - organoir@westwicke.com http://www.organogenesis.com

• General Corporate Information    Officers Gary S. Gillheeney, Sr. - Chairman; Chief Executive Officer and President David Francisco - Chief Financial Officer Alan A. Ades - Director Robert Ades - Director Michael J. Driscoll - Director Peer Information Organogenesis (GSAC) Organogenesis (CASI) Organogenesis (ALCD.) Organogenesis (OMNN) Organogenesis (CGPI.) Organogenesis (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 68621F102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 126.91 Most Recent Split Date: (:1) Beta: 1.38 Market Capitalization: $657.41 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.18 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: 28.78 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.58 Price/Cash Flow: 24.82 Price / Sales: 1.41 EPS Growth vs. Year Ago Period: 100.00% vs. Previous Quarter: 300.00% Sales Growth vs. Year Ago Period: 30.98% vs. Previous Quarter: 49.36% ROE 12/31/25 - - 09/30/25 - 4.01 06/30/25 - -0.37 ROA 12/31/25 - - 09/30/25 - 2.06 06/30/25 - -0.20 Current Ratio 12/31/25 - - 09/30/25 - 3.32 06/30/25 - 3.95 Quick Ratio 12/31/25 - - 09/30/25 - 2.88 06/30/25 - 3.45 Operating Margin 12/31/25 - - 09/30/25 - 2.14 06/30/25 - -0.22 Net Margin 12/31/25 - - 09/30/25 - -1.30 06/30/25 - -1.92 Pre-Tax Margin 12/31/25 - - 09/30/25 - -1.33 06/30/25 - -5.01 Book Value 12/31/25 - - 09/30/25 - 2.01 06/30/25 - 1.84 Inventory Turnover 12/31/25 - - 09/30/25 - 3.70 06/30/25 - 3.78 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.01 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 34.26 06/30/25 - 35.45

Powered by Zacks Investment Research ©